Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Time to Sell?

Posted by Renee Jackson on Nov 6th, 2026

Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) shares gapped down prior to trading on Wednesday. The stock had previously closed at $16.00, but opened at $14.90. Ono Pharmaceutical shares last traded at $14.90, with a volume of 1,000 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research cut Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 4th. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

View Our Latest Research Report on Ono Pharmaceutical

Ono Pharmaceutical Price Performance

The company’s 50 day moving average is $15.02 and its 200 day moving average is $14.88. The company has a current ratio of 3.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $7.00 billion, a price-to-earnings ratio of 14.75 and a beta of 0.39.

Ono Pharmaceutical Company Profile

(Get Free Report)

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.